Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (111-120 of 323) with videos related to

Pageof 33
Sort By:
American Journal of Hematology|December 28, 2017
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM reboundJoshua N Gustine, Kirsten Meid, Toni Dubeau, et al.
British Journal of Haematology|March 14, 2018
Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemiaJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2018
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström MacroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Best Practice & Research. Clinical Haematology|November 10, 2016
Epigenomics in Waldenstrom's macroglobulinaemiaAntonio Sacco, Adriano Fenotti, Stefano Bazzana, et al.
Blood|May 16, 2002
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
Blood|April 18, 2020
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patientsSteven P Treon, Jorge J Castillo, Alan P Skarbnik, et al.
Clinical Lymphoma|March 30, 2005
CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemiaZachary R Hunter, Andrew R Branagan, Robert Manning, et al.
British Journal of Haematology|May 10, 2017
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemiaJoshua N Gustine, Kirsten Meid, Toni Dubeau, et al.
Blood|May 31, 2002
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell LymphomaJohn M Hatcher, Guang Yang, Li Wang, et al.
Pageof 33

Showing results (111-120 of 323) with videos related to

Sort By:
Pageof 33
American Journal of Hematology|December 28, 2017
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM reboundJoshua N Gustine, Kirsten Meid, Toni Dubeau, et al.
British Journal of Haematology|March 14, 2018
Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemiaJorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2018
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström MacroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Best Practice & Research. Clinical Haematology|November 10, 2016
Epigenomics in Waldenstrom's macroglobulinaemiaAntonio Sacco, Adriano Fenotti, Stefano Bazzana, et al.
Blood|May 16, 2002
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
Blood|April 18, 2020
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patientsSteven P Treon, Jorge J Castillo, Alan P Skarbnik, et al.
Clinical Lymphoma|March 30, 2005
CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemiaZachary R Hunter, Andrew R Branagan, Robert Manning, et al.
British Journal of Haematology|May 10, 2017
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemiaJoshua N Gustine, Kirsten Meid, Toni Dubeau, et al.
Blood|May 31, 2002
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell LymphomaJohn M Hatcher, Guang Yang, Li Wang, et al.
Pageof 33